Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Medipattern closes US$5.2 million bought-deal financing

Fasken
Reading Time 1 minute read Subscribe
Client

Research Capital

On August 2, 2007, Medipattern Corporation announced that it had closed its bought deal with Research Capital Corporation. Medipattern issued 4,730,000 common shares at a price of $1.10 per share for aggregate gross proceeds of $5,203,000. On August 17, Research Capital partially exercised an over-allotment option for additional proceeds of $521,290, for aggregate gross proceeds of the offering of $5,724,290. Medipattern is an award-winning developer of computer-aided diagnosis (CAD) medical imaging software designed to detect cancer and permit a higher standard of care for the millions of patients at risk of cancer. Research Capital was advised in this transaction by Rubin Rapuch, Jeffrey Klam, Catherine Fraser, David Turgeon and Leanne Shaughnessy of Fasken Martineau.

    Subscribe

    Receive email updates from our team

    Subscribe